drugset / Trial / NCT02020161

Clinical Guidelines for APL Treatment

NCT02020161

Phase 4 Unknown 200 enrolled PETHEMA Foundation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed

Timeline

Start
2012-06
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Idarubicin Small molecule
Subject Methotrexate Small molecule
Subject Tretinoin Small molecule